Publications by authors named "Aristides Anastasakis"
A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making.
Eur Heart J Qual Care Clin Outcomes
June 2024
Aims: To conduct a contemporary cost-effectiveness analysis examining the use of implantable cardioverter defibrillators (ICDs) for primary prevention in patients with hypertrophic cardiomyopathy (HCM).
Methods: A discrete-time Markov model was used to determine the cost-effectiveness of different ICD decision-making rules for implantation. Several scenarios were investigated, including the reference scenario of implantation rates according to observed real-world practice.
Article Synopsis
- Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) can still face life-threatening arrhythmic events (LTAEs) even when on β-blocker treatment, highlighting the need for careful management strategies.
- The study investigated long-term outcomes of CPVT patients carrying RYR2 variants who were treated solely with β-blockers, focusing on the incidence of LTAEs and evaluating the cost-effectiveness of an implantable cardioverter defibrillator (ICD).
- Out of 216 patients monitored for an average of 9.4 years, 13% experienced an LTAE, with certain risk factors identified, such as syncope and specific genetic variants, that increased the likelihood of these dangerous events
Impact of social containment measures on cardiovascular admissions and sudden cardiac death rates during Coronavirus Disease (COVID-19) outbreak in Greece.
Hellenic J Cardiol
August 2021
Article Synopsis
- Andersen-Tawil Syndrome type 1 (ATS1) is a rare heart condition linked to mutations in the KCNJ2 gene, with a study focusing on its risks and treatment outcomes across a large patient cohort.
- Out of 118 studied patients, 17 experienced life-threatening arrhythmic events (LAE) over an average follow-up of 6.2 years, with syncope and sustained ventricular tachycardia identified as significant risk factors.
- The study concluded that antiarrhythmic therapy, especially amiodarone, may increase the risk of LAE in ATS1 patients, highlighting the need for careful management of these patients.
Importance: It is unclear whether hypertrophic cardiomyopathy (HCM) conveys excess mortality when compared with the general population.
Objective: To compare the survival of patients with HCM with that of the general European population.
Design, Setting, And Participants: Retrospective cohort study of 4893 consecutive adult patients with HCM presenting at 7 European referral centers between 1980 and 2013.
Importance: Sudden cardiac death (SCD) is the most common mode of death in childhood hypertrophic cardiomyopathy (HCM), but there is no validated algorithm to identify those at highest risk.
Objective: To develop and validate an SCD risk prediction model that provides individualized risk estimates.
Design, Setting, And Participants: A prognostic model was developed from a retrospective, multicenter, longitudinal cohort study of 1024 consecutively evaluated patients aged 16 years or younger with HCM.
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Heart
April 2019
Objective: In 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%-<6% and ≥6%, respectively).
Methods: The protocol was registered with PROSPERO (registration number: CRD42017064203).
Objectives: Atrial fibrillation (AF) is associated with increased morbidity and mortality in patients with hypertrophic cardiomyopathy (HCM). The primary aim of this study (HCM Risk-AF) was to determine the predictors of AF in a large multicentre cohort of patients with HCM. Exploratory analyses were performed to investigate the association between AF and survival and the efficacy of antiarrhythmic therapy in maintaining sinus rhythm (SR).
View Article and Find Full Text PDFBackground: Hypertrophic cardiomyopathy is associated with sudden cardiac death (SCD). Some studies have shown an association between risk of sudden death and left ventricular maximal wall thickness (MWT), but there are few data in patients with extreme hypertrophy. The aim of this study was to determine the relation between MWT and the risk of SCD.
View Article and Find Full Text PDFAims: Atrial fibrillation (AF) and thrombo-embolism (TE) are associated with reduced survival in hypertrophic cardiomyopathy (HCM), but the absolute risk of TE in patients with and without AF is unclear. The primary aim of this study was to derive and validate a model for estimating the risk of TE in HCM. Exploratory analyses were performed to determine predictors of TE, the performance of the CHA2 DS2 -VASc score, and outcome with vitamin K antagonists (VKAs).
View Article and Find Full Text PDFAims: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only a crude estimate of risk and fail to account for the different effect size of individual risk factors. The aim of this study was to develop and validate a new SCD risk prediction model that provides individualized risk estimates.
View Article and Find Full Text PDF